News

Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
PMLive12h
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership
Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...
STAT2d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Novo Nordisk CEO Jorgensen to Leave After Fall in Share Price
Novo Nordisk A/S ousted Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker struggles with growing competition ...
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...